Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in obese, nondiabetic adults is associated with a markedly reduced risk of developing nonexudative age-related macular degeneration (AMD).
The protective effect of GLP-1RAs persists at 5, 7, and 10 years of follow-up compared to other weight-loss drugs (OWLDs).
GLP-1RA treatment does not appear to influence progression from nonexudative to exudative AMD.
Findings highlight potential ocular benefits of GLP-1RAs outside diabetes and support further prospective trials in diverse populations.
